Daily oral edaravone (Radicava ORS) was not superior to the FDA-approved on/off regimen in amyotrophic lateral sclerosis (ALS ...

Weiss highlighted a 2012 Cochrane Library review that examined research and found the drug is “reasonably safe” and prolongs ...

SAVANNAH, Georgia — Heart problems are common in the vast majority of neuromuscular disorders, and cardiac monitoring of ...

One year after starting efgartigimod (Vyvgart) treatment, most generalized myasthenia gravis (gMG) patients significantly ...

The findings, presented at the Myasthenia Gravis Foundation of America (MGFA) session of the American Association of ...

"Inebilizumab is a humanized monoclonal antibody that causes targeted and sustained depletion of CD19-positive B cells, ...

For immediate release Nipocalimab demonstrates sustained disease control in adolescents living with generalised myasthenia ...

UCB will contribute 14 presentations, including an oral presentation, selected to feature across the AANEM and MGFA meeting, emphasizing UCB's leadership in neuromuscular researchPresentations ...

Johnson & Johnson has burnished the evidence for nipocalimab, adding a sliver of data in adolescents with generalized ...

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced three presentations at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting being held in ...

Johnson & Johnson (NYSE: JNJ) today announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab in anti-AChRa positive adolescents (aged 12 – 17 years) living with generalized ...

Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of resp ...